COR. 1995. PROJECTES FINANÇATS

Dr  Lina Badimon

Cases-Langhoff C, Castelló A, Badimon L. The nucleotide sequence data. EMBL/GenBank/DDBJ nucleotide sequence accesion numbers Aj011767 (pNOR-1 a) and AJ011768 (p-NOR-1 b').

Rodriguez-Sinovas C, Martínez-González J, Sánchez-Gómez S, Badimon L. LDL downregulate CYP51 in vascular endothelial cells and in the arterial wall through a SREBP-2 dependent mechanism. Circulation Research 88: 268-274; 2001

Rodriguez-Campos A, Ruiz-Enriquez P, Badimon L. Vascular smooth muscle cell p53 is lost before entering migration and proliferation. Arteriosclerosis, Thrombosis and Vascular Biology 21: 214-219; 2001

Johnson GJ, Griggs TR, Badimon L. The utility of animal models in the preclinical study of interventions to prevent human coronary artery restenosis : analysis and recommendations. Thrombosis and Haemostasis 81: 835-843; 1999

Badimon JJ, Lettino M, Toschi V, Fuster V, Berrozpe M, Chesebro JH, Badimon L. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques. Effects of TFPI on plaque thrombogenicity under flow conditions. Circulation 99 : 1780-1787; 1999

Rius J, Martinez-González J, Crespo-Asensio J, Badimon L.  LDL activate NOR-1 expression by a PKA, PKC and CREB dependent mechanism in human vascular smooth mucle cells. European Journal for Clinical Investigation, 31: 23; 2001

Rius J, Martínez-González J, Badimon L. Las LDL inducen en células musculares lisas humanas un receptor nuclear (Nor-1) identificado en placas ateroscleróticas. Clinica e Investigación en Arteriosclerosis 12 (suppl 1): 16 ; 2000

Castello A, Cases-Langhoff C, Martínez-González J, Badimon L. De-differentiated smooth muscle cells in human coronary atherosclerotic lesions express a new mitogen-inducible nuclear orphan receptor gene. European Heart Journal 20 (suppl): 357; 1999

Berrozpe M, Badimon L. Angiogenesis in atherosclerotic lesions of human coronary arteries. European Journal of Clinical Investigation 29(suppl 1): 10; 1999

Berrozpe M, Badimon L. Tissue factor in atherosclerotic lesion progression. European Journal of Clinical Investigation 29(suppl 1): 11; 1999

Badimon L, Cases C, Castelló A. Smooth muscle cell proliferation : new genes involved in the initiation of the cell cycle. Drugs Affecting Lipid Metabolism 21; 1998

Cases C, Badimon L. A nuclear hormone receptor gene is up-regulated by thrombin in smooth muscle cells. European Journal of Clinical Investigation 27 (Supl. 1): A28; 1997

Berrozpe M, Badimon L. La presencia de neovasos en placas ateroscleroticas de coronarias humanas esta relacionada con el grado de severidad de la lesion. Clínica e Investigación en Arteriosclerosis 9 (Supl.1): 29; 1997

Cases-Langhoff C, Badimon L. La inducción de actividad proliferante en célula muscular lisa coronaria se asocia con la expresión diferencial de trombospondina. Clinica e Investigación en Arteriosclerosis 8 (Supl.1) : 2 ; 1996

Dr  Francisco Blanco-Vaca

Escolá-Gil JC, Jorba O, Julve-Gil J, González-Sastre F, Ordóñez-Llanos J, Blanco-Vaca F. Pitfalls of direct HDL-cholesterol measurements in mouse models of hyperlipidemia and atherosclerosis.Clinical Chemistry 1999; 45: 1567-1569.

Escolà-Gil JC, Marzal A, Casacuberta J, Julve-Gil BY, Ishida J, Ordóñez-Llanos J, Chan L, González-Sastre F, Blanco-Vaca F. Human apolipoprotein A-II is a pro-atherogenic molecule when it is expressed in transgenic mice at a level similar to that in humans: evidence of a potentially relevant species-specific interaction with diet.Journal of Lipid Research 1998; 39: 457-462

Julve-Gil J, Ruíz-Pérez E, Casaroli-Marano RP, Marzal-Casacuberta A, Escolà-Gil JC, González-Sastre F, Blanco-Vaca F. Free cholesterol deposition in corneas of human apoA-II transgenic mice with functional LCAT deficienci.Metabolism 1999; 48: 415-421.

Julve J, Escolà-Gil JC, Marzal-Casacuberta À, Ordóñez-Llanos J, González-Sastre F, Blanco-Vaca F. Increased production of very-low density lipoproteins in trangenic mice overexpressing human apolipoprotein A-II and fed with a high-fat diet. Biochimica Biophysica Acta 2000; 1488:233-244.

Escolà-Gil JC, Julve J, Marzal-Casacuberta À, Ordóñez-Llanos J,González-Sastre F, Blanco-Vaca F. Expression of human apolipoprotein A-II in apolipoprotein-E deficient mice induces features of familial combined hyperlipidemia. Journal of Lipid Research 2000; 41: 1328-1338.

Escolà-Gil JC, Julve J, Marzal-Casacuberta À, Ordóñez-Llanos J,González-Sastre F, Blanco-Vaca F. ApoA-II expression in CETP transgenic mice increases VLDL production and impairs VLDL clearance. Journal of Lipid Research 2001; 42: 241-248.

Marzal Casacuberta À, Escolà Gil JC, Julve Gil, González Sastre F, Blanco Vaca F. Modificación genética de animales de laboratorio (I): metabolismo lipoproteico y arteriosclerosis. Clínica e Investigación en Arteriosclerosis 1998; 10: 19-31.

Marzal Casacuberta À, Escolà Gil JC, Julve Gil, González Sastre F, Blanco Vaca F. Modificación genética de animales de laboratorio (II): metabolismo lipoproteico y arteriosclerosis. Clínica e Investigación en Arteriosclerosis 1998; 10: 78-87

Blanco Vaca F, Marzal Casacuberta À, González Sastre F. Lipoproteïnes d'alta densitat (HDL): bases moleculars del metabolisme i relació amb l'arteriosclerosi (capitol de llibre) pàgines 267-300 En: Lliçons de Patologia Molecular, Ed.Springer-Verlag Ibérica i Edicions Universitat de Barcelona, 2000. Editors: Francesc González Sastre i Joan J.Guinovart.

Dr  Joan Cinca Cuscullola

Cinca J, Rodríguez-Sinovas A. Cardiovascular reflex responsos induced by epicardial chemoreceptor stimulation.Cardiovasc Res 2000; 45: 163-171.

Cinca J, Rodríguez-Sinovas A, Anivarro I, Moure C, Tresánchez M, Soler-Soler J. Neurally mediated depressor hemodynamic response induced by intracoronary catheter balloon inflation in pigs.Cardíovasc Res 2000; 46: 198-206.

Dr  Jordi Félez Brugués

Arza B, Félez J, Fábregas P, Laroche Y, Collen D, Lijnen HR. Plasminogen binding properties of macrophage inflammatory protein (MIP)-2ª .Thromb Haemost 84:71-7, 2000

Félez J. Angiostatina: angiogenesis y actividad anti-tumoral.Rev Iberoam Tromb Hemost 11(1): 50-53, 1998

Félez J, Jardí M, Arza B. Angiostatina y su actividad anti-tumoral.Medicina Clínica, 114: 431-6, 2000

Félez J, ed. La trombolisis 30 años más tarde: la perspectiva del especialista en coagulación.Editorial Edikamed, Granada, 1998

Arza B, Félez J. The emerging impact of phage display technology in thrombosis and haemostasis.Thromb Haemost 80:354-65, 1998

Sinniger V, Merton E, Fàbregas P, Félez J, Longstaff C. Regulation of tissue plasminogen activator (tPA) activity by cells: domains responsible for binding and mechanism of stimulation.J Biol Chem 274:12414-12422, 1999

Félez J. Angisotatin: angiogenesis and anti-tumoral activity.Haematologica 83 (Supl. 1): 358-361, 1998

Longstaff C, Merton ER, Fàbregas P, Félez J. Characterization of cell associated plasminogen activation catalysed by urokinase-type plasminogen activator (uPA) but independent of uPAR.(CD87 Blood 93:3839-3846, 1999

Félez J. Plasminogen binding to cell surfaces.Fibrinolysis & Proteolysis 12(4):183-189, 1998

Arza B, Hoylaerts MF, Félez J, Collen D, Lijnen HR. Prostromelysin-1 (ProMMP-3) stimulates plasminogen activation by tissue-type plasminogen activation. EUROPEAN J BIOCHEM 267: 6378-84, 2000.

Herren T, Burke T.A., Jardí M, Félez J, Plow E.F. Regulation of plasminogen binding to neutrophils. BLOOD 97: 1070-78, 2001.

Arza B, DeMaeyer M, Félez J, Collen D, Lijnen HR. Critical Role of Glutamic Acid 202 in The Enzymatic Activity of Stromelysin-1 (MMP-3). EUROPEAN J BIOCHEM 268: 826-831, 2001.

Gong Y, Kim SO, Felez J, Grella DK, Castellino FJ, Miles LA. Conversion of Glu-plasminogen to Lys-plasminogen is necessary for optimal stimulation of plasminogen activation on the endothelial cell surface. J BIOL CHEM 276:19078-83, 2001.

Dr  Fausto García Hegardt

Mascaró C, Ortiz JA, Ramos MM, Haro D, Hegardt FG. SREBP-mediated effect of fluvastatin on cytosolic HMG-CoA synthase transcription.Archives of Biochemistry and Biophysics (2000) 374, 286-292

Mascaró C, Nadal A, Hegardt FG, Marrero PJ, Haro D. Contribution of Steroidogenic Factor-1 to the regulation of cholesterol synthesis.Biochemical Journal (2000) 350, 785-790

Dr  Magda Heras Fortuny

F Epelde, M Rigol, M Heras, E Roig, N Solanes, F. Pérez-Villa, G. Sanz. Concentracions elevades d'angiotensina I1 modifiquen la regulació del flux coronari durant la taquicardia. Rev Societat Catalana Cardio 1998; 3 (Supl): 41.

M Heras, M Rigol, E Roig, F Epelde, N Solanes, F Pérez-Villa, G Sanz. High plasma levels of angiotensin II impairs flow regulation during tachycardia. Eur Heart J 1998; 19 (Abstr. Suppl): 276.

F Epelde, M Rigol, M Heras, E Roig, N Solanes, F Pérez-Villa. Concentraciones elevadas de angiotensina 11 modifican la regulación del flujo coronario durante la taquicardia. Rev Esp Cardiol1998; 51 (Suppl 5): 94.

Dr  Teresa Royo i Bargues

Royo T, Vidal M, Badimon L. La plaqueta en la aterosclerosis coronaria acelerada: purificación del receptor GP IIb/IIIa y preparación de anticuerpos para estudios en modelo porcino.Clínica e Investigación en Arteriosclerosis 1998; 10(5):217-228.

Badimon L, Martínez-González J, Royo T. Patologia de la progressió de la malaltia arterial coronària a nivell molecular.Patologia Molecular, Treballs de la Societat Catalana de Biologia 1999, Vol. 49.

Royo T, Vidal M, Badimon L. Porcine platelet von Willebrand Antigen II (vW AgII): Inhibitory effecton collagen induced aggregation and comparative distribution with human platelets.Thromb Haemost 1998; 80:677-685.

García-Moll X, Royo T, Badimon L. Arterosclerosis y trombosis.Revista Latina de Cardiología 1998; 19(4):140-155.

Royo T, Vidal M, Badimon L. Purification of the porcine platelet GP IIb-IIIa complex and the propolypeptide of von Willebrand factor.Thromb Haemost 1998; 80:302-309.